Importantly, SETD2 CNV loss was significantly more common in ATRX-mutant glioma (14.4%) as compared to ATRX-wildtype glioma (7.9%) (Supplementary Fig. S1B and C). The gene discussed is ATRX; the disease is central nervous system cancer.